Axsome Therapeutics (AXSM) Goodwill (2022 - 2026)

Axsome Therapeutics has disclosed Goodwill across 5 years of filings, most recently posting $12.0 million for Q1 2026.

• Goodwill for Q1 2026 came in at $12.0 million, changed 0.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.0 million (changed 0.35% YoY), and the FY2025 annual result was $12.0 million, changed 0.35% from the prior year.
• Goodwill came in at $12.0 million for Q1 2026 at Axsome Therapeutics, roughly flat from $12.0 million in the prior quarter.
• In the past five years, Goodwill ranged from a high of $12.0 million in Q2 2023 to a low of $10.3 million in Q4 2022.
• The 5-year median for Goodwill is $12.0 million (2023), against an average of $11.8 million.
• Across the five-year window, Goodwill grew 16.39% in 2023 and fell 0.35% in 2024, its largest moves.
• Axsome Therapeutics' Goodwill stood at $10.3 million in 2022, then advanced by 16.39% to $12.0 million in 2023, then changed by 0.0% to $12.0 million in 2024, then climbed by 0.35% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
• The last three Goodwill figures came in at $12.0 million (Q1 2026), $12.0 million (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.